Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Guanfacine
Drug ID BADD_D01046
Description Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release tablet for the treatment of ADHD.[L11277] Guanfacine was first described in the literature in 1974.[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274]
Indications and Usage Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.[L11277]
Marketing Status approved; investigational
ATC Code C02AC02
DrugBank ID DB01018
KEGG ID D08031
MeSH ID D016316
PubChem ID 3519
TTD Drug ID Not Available
NDC Product Code 0591-0444; 0591-0453; 27241-243; 42291-326; 60505-3928; 62135-728; 70436-040; 72162-2029; 16714-191; 16714-192; 42806-296; 60429-960; 70436-042; 71205-946; 0228-2855; 53746-711; 60505-3929; 60505-3930; 63629-1102; 63629-8203; 70518-1369; 71205-945; 63304-927; 65162-713; 70436-039; 70518-2771; 24658-730; 24979-198; 0228-2851; 63629-1105; 16714-190; 16714-193; 24979-538; 60429-961; 62135-727; 63629-8161; 70518-1371; 71205-947; 24979-199; 24979-536; 50268-374; 63304-926; 24658-731; 42806-048; 53746-713; 54092-515; 60429-962; 60429-963; 60505-3927; 63629-1103; 65162-711; 70436-041; 71335-9750; 72162-2030; 42291-327; 0228-2850; 0228-2853; 54092-517; 63187-302; 63304-924; 63304-925; 71205-944; 24979-534; 27241-242; 42291-325; 50090-5991; 54092-519; 63629-1104; 68094-065; 70518-0793; 0904-7140; 24979-533; 42291-324; 50090-6073; 50090-6493; 54092-513
UNII 30OMY4G3MK
Synonyms Guanfacine | Tenex | Guanfacine Hydrochloride | Hydrochloride, Guanfacine | Guanfacine Monohydrochloride | Monohydrochloride, Guanfacine | Lon798 | BS-100-141 | BS 100 141 | BS100141 | Estulic
Chemical Information
Molecular Formula C9H9Cl2N3O
CAS Registry Number 29110-47-2
SMILES C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.0040.001470%Not Available
Loss of libido19.08.03.003--Not Available
Malaise08.01.01.0030.000900%
Mania19.16.02.0020.000381%
Mental impairment19.21.02.003; 17.03.03.0020.000519%Not Available
Middle insomnia19.02.01.003; 17.15.03.0030.000467%Not Available
Mood altered19.04.02.0070.001176%Not Available
Mood swings19.04.03.0010.000640%Not Available
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Negativism19.05.01.0120.000969%Not Available
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.0030.000588%Not Available
Nocturia20.02.03.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Optic neuritis10.02.01.097; 17.04.05.001; 06.04.08.0020.000173%Not Available
Orthostatic hypotension17.05.01.020; 24.06.03.0040.000259%Not Available
Pain in extremity15.03.04.010--
Pallor24.03.04.001; 23.03.03.031; 08.01.03.0320.000381%Not Available
Palpitations02.11.04.0120.000259%
Panic attack19.06.04.001--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Paresis17.01.04.008--Not Available
Peripheral coldness23.06.04.008; 24.04.03.006; 08.01.09.0100.002059%Not Available
Petit mal epilepsy17.12.04.0010.000173%Not Available
Pollakiuria20.02.02.0070.000173%
Polyneuropathy17.09.03.0120.000173%Not Available
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages